Latest Breaking News On - Roger aston - Page 1 : comparemela.com

Immuron Board Changes

MELBOURNE, Australia, May 31, 2024 Immuron Limited , an Australian based and globally integrated biopharmaceutical company, advises that Dr Roger Aston has resigned from his position as.

United statesUnited kingdomRoger astonJeannie joughinSteven lydeamoreFlagellin searsPaul brennanSecurities exchangeBristol myers squibbImmuron limitedImmuron platform technologyNon executive directorNon executive chairmanAustralian registerTherapeutic goodsOpin infect

Immuron Board Changes - Immuron (NASDAQ:IMRN)

MELBOURNE, Australia, May 31, 2024 (GLOBE NEWSWIRE) Immuron Limited ((ASX: IMC, NASDAQ:IMRN), an Australian based and globally integrated biopharmaceutical company, advises that Dr Roger Aston has resigned from his

United kingdomUnited statesJeannie joughinSteven lydeamoreFlagellin searsPaul brennanRoger astonSecurities exchangeBristol myers squibbImmuron limitedImmuron platform technologyNon executive directorNon executive chairmanAustralian registerTherapeutic goodsOpin infect

Roger Aston Acquires 3,649,904 Shares of PharmAust Limited (ASX:PAA) Stock

Roger Aston Acquires 3,649,904 Shares of PharmAust Limited (ASX:PAA) Stock
themarketsdaily.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from themarketsdaily.com Daily Mail and Mail on Sunday newspapers.

United statesRoger astonPharmaust limitedGet free reportAust limitedPharmaust daily

Immuron : Chairman Transition

Immuron Chairman Transition Melbourne, Australia, June 30, 2023: Immuron Limited , an Australian based and globally integrated biopharmaceutical company, is pleased to announce.

New zealandRoger astonSteven lydeamorePaul brennanDrug administrationImmuron limitedPolynovo limitedImmuron chairmanNon executive directorInvestigational new drug applicationsChief executive officerMarketing director australiaSales director new zealandNephew healthcareAustralian registerTherapeutic goods

Immuron Chairman Transition

MELBOURNE, Australia, June 30, 2023 Immuron Limited , an Australian based and globally integrated biopharmaceutical company, is pleased to announce the transition of Paul Brennan from.

New zealandRoger astonPaul brennanSteven lydeamorePolynovo limitedDrug administrationImmuron limitedNon executive directorInvestigational new drug applicationsChief executive officerMarketing director australiaSales director new zealandNephew healthcare